Agios Pharmaceuticals, Inc. (AGIO) FinancialsAGIOAgios Pharmaceuticals, Inc.

Evaluating the bottom line, Agios Pharmaceuticals, Inc. maintains a gross margin of 93.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -247.07%, while the net margin is -225.06%. These profitability ratios, combined with a Return on Equity (ROE) of -34.34%, provide a clear picture of how effectively AGIO converts its operational activities into shareholder value.

In the context of the broader market, AGIO competes directly with industry leaders such as PRGO and ZYME. With a market capitalization of $2.05B, it holds a significant position in the sector. When comparing efficiency, AGIO's gross margin of 93.30% stands against PRGO's 30.69% and ZYME's 100.00%. Such benchmarking helps identify whether Agios Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Agios reported a remarkable revenue increase of 259.1% year-over-year in Q2 2026, with total revenue reaching $44.75 million. Despite this, the company continues to face net losses, with a reported loss of $100.7 million in the same quarter.